Compass Therapeutics (CMPX) News Today $1.50 -0.01 (-0.66%) (As of 12/24/2024 02:33 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period D. Boral Capital Initiates Coverage on Compass Therapeutics (NASDAQ:CMPX)December 25 at 1:19 AM | americanbankingnews.comCompass Therapeutics initiated with a Buy at D. Boral CapitalDecember 24 at 11:06 PM | markets.businessinsider.comD. Boral Capital Initiates Coverage of Compass Therapeutics (CMPX) with Buy RecommendationDecember 24 at 3:31 AM | msn.comCompass Therapeutics, Inc. (NASDAQ:CMPX) Given Consensus Rating of "Moderate Buy" by AnalystsCompass Therapeutics, Inc. (NASDAQ:CMPX - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the five brokerages that are presently covering the company, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold rating and three have assigDecember 23 at 8:54 AM | marketbeat.comCompass Therapeutics (NASDAQ:CMPX) Coverage Initiated at D. Boral CapitalD. Boral Capital began coverage on Compass Therapeutics in a research note on Monday. They issued a "buy" rating and a $32.00 price objective on the stock.December 23 at 8:06 AM | marketbeat.comCompass Therapeutics, Inc. (NASDAQ:CMPX) Short Interest UpdateCompass Therapeutics, Inc. (NASDAQ:CMPX - Get Free Report) was the target of a significant growth in short interest during the month of November. As of November 30th, there was short interest totalling 1,450,000 shares, a growth of 17.9% from the November 15th total of 1,230,000 shares. Based on an average trading volume of 487,900 shares, the days-to-cover ratio is presently 3.0 days. Approximately 1.7% of the shares of the stock are sold short.December 16, 2024 | marketbeat.comJanus Henderson Group PLC Has $3.36 Million Stake in Compass Therapeutics, Inc. (NASDAQ:CMPX)Janus Henderson Group PLC decreased its stake in Compass Therapeutics, Inc. (NASDAQ:CMPX - Free Report) by 64.7% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,843,286 shares of the company's stock aDecember 12, 2024 | marketbeat.comCompass Therapeutics Appoints New CFO Amid Strategic MovesDecember 11, 2024 | markets.businessinsider.comCompass Therapeutics Names Barry Shin Chief Financial OfficerDecember 10, 2024 | marketwatch.comCompass Therapeutics Appoints Biopharmaceutical Industry Leader Barry Shin as Chief Financial OfficerDecember 10, 2024 | markets.businessinsider.comCompass Therapeutics Appoints Biopharmaceutical Industry Leader Barry Shin as Chief Financial OfficerDecember 10, 2024 | globenewswire.comCompass Therapeutics: Near-Term Readout, But Beware The High Stakes In Biliary CancerDecember 9, 2024 | seekingalpha.comCompass Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare ConferenceDecember 2, 2024 | globenewswire.comCompass Therapeutics (NASDAQ:CMPX) Downgraded to "Hold" Rating by Leerink PartnrsLeerink Partnrs cut shares of Compass Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Friday.November 16, 2024 | marketbeat.comCompass downgrade ‘curious,’ presents upside, says H.C. WainwrightNovember 15, 2024 | markets.businessinsider.comHold Rating Issued for Compass Therapeutics Amid CTX-009 Uncertainty and Strategic ConcernsNovember 15, 2024 | markets.businessinsider.comCompass Therapeutics downgraded to Market Perform from Outperform at LeerinkNovember 15, 2024 | markets.businessinsider.comCompass Therapeutics (NASDAQ:CMPX) Lowered to Market Perform Rating by Leerink PartnersLeerink Partners cut Compass Therapeutics from an "outperform" rating to a "market perform" rating and dropped their price objective for the company from $5.00 to $4.00 in a report on Friday.November 15, 2024 | marketbeat.comResearch Analysts Issue Forecasts for CMPX FY2024 EarningsCompass Therapeutics, Inc. (NASDAQ:CMPX - Free Report) - Equities researchers at HC Wainwright increased their FY2024 earnings estimates for Compass Therapeutics in a research note issued to investors on Tuesday, November 12th. HC Wainwright analyst J. Pantginis now expects that the company willNovember 15, 2024 | marketbeat.comWedbush Predicts Higher Earnings for Compass TherapeuticsCompass Therapeutics, Inc. (NASDAQ:CMPX - Free Report) - Investment analysts at Wedbush boosted their FY2024 earnings per share estimates for shares of Compass Therapeutics in a research note issued on Tuesday, November 12th. Wedbush analyst R. Driscoll now expects that the company will post earnNovember 15, 2024 | marketbeat.comResearch Analysts Offer Predictions for CMPX FY2028 EarningsCompass Therapeutics, Inc. (NASDAQ:CMPX - Free Report) - Investment analysts at HC Wainwright raised their FY2028 earnings per share estimates for Compass Therapeutics in a report released on Tuesday, November 12th. HC Wainwright analyst J. Pantginis now expects that the company will post earningNovember 14, 2024 | marketbeat.comCompass Therapeutics Reports Q3 2024 Financials and Clinical ProgressNovember 14, 2024 | markets.businessinsider.comCompass Therapeutics price target raised to $7 from $5 at LadenburgNovember 13, 2024 | markets.businessinsider.comCompass Therapeutics to Participate in Upcoming Investor EventsNovember 13, 2024 | globenewswire.comCompass Therapeutics Reports 2024 Third Quarter Financial Results and Provides Corporate UpdateNovember 12, 2024 | globenewswire.comCompass Therapeutics' (CMPX) Buy Rating Reiterated at HC WainwrightHC Wainwright reaffirmed a "buy" rating and issued a $10.00 price target on shares of Compass Therapeutics in a research report on Monday.November 11, 2024 | marketbeat.comStrategic Foresight and Proactive Measures Underpin Buy Rating for COMPASS PathwaysNovember 1, 2024 | markets.businessinsider.comCompass Therapeutics, Inc. (NASDAQ:CMPX) Short Interest Up 8.3% in SeptemberCompass Therapeutics, Inc. (NASDAQ:CMPX - Get Free Report) was the recipient of a large growth in short interest in September. As of September 30th, there was short interest totalling 2,490,000 shares, a growth of 8.3% from the September 15th total of 2,300,000 shares. Based on an average daily trading volume, of 423,800 shares, the days-to-cover ratio is currently 5.9 days. Approximately 2.9% of the company's stock are short sold.October 17, 2024 | marketbeat.comCompass Therapeutics (NASDAQ:CMPX) Stock, Short Interest ReportOctober 8, 2024 | benzinga.comCompass Therapeutics Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual MeetingOctober 4, 2024 | globenewswire.comCompass Therapeutics, Inc. (NASDAQ:CMPX) Sees Significant Increase in Short InterestCompass Therapeutics, Inc. (NASDAQ:CMPX - Get Free Report) was the target of a significant growth in short interest during the month of September. As of September 15th, there was short interest totalling 2,300,000 shares, a growth of 23.7% from the August 31st total of 1,860,000 shares. Based on an average daily trading volume, of 437,600 shares, the days-to-cover ratio is currently 5.3 days. Currently, 2.7% of the shares of the company are sold short.September 30, 2024 | marketbeat.comKaryopharm Therapeutics Inc. (25K.F) Stock Price, News, Quote & History - Yahoo FinanceSeptember 23, 2024 | finance.yahoo.comCompass Therapeutics (NASDAQ:CMPX) Rating Increased to Buy at LADENBURG THALM/SH SHLADENBURG THALM/SH SH raised Compass Therapeutics from a "neutral" rating to a "buy" rating and set a $5.00 target price for the company in a research report on Monday.September 16, 2024 | marketbeat.comCompass Therapeutics to Participate in Upcoming Investor EventsSeptember 3, 2024 | globenewswire.comInstitutional investors own a significant stake of 50% in Compass Therapeutics, Inc. (NASDAQ:CMPX)August 23, 2024 | finance.yahoo.comWedbush Weighs in on Compass Therapeutics, Inc.'s Q3 2024 Earnings (NASDAQ:CMPX)Compass Therapeutics, Inc. (NASDAQ:CMPX - Free Report) - Stock analysts at Wedbush dropped their Q3 2024 EPS estimates for Compass Therapeutics in a note issued to investors on Wednesday, August 14th. Wedbush analyst R. Driscoll now forecasts that the company will earn ($0.11) per share for the qAugust 16, 2024 | marketbeat.comWedbush Research Analysts Boost Earnings Estimates for Compass Therapeutics, Inc. (NASDAQ:CMPX)Compass Therapeutics, Inc. (NASDAQ:CMPX - Free Report) - Investment analysts at Wedbush raised their FY2028 EPS estimates for Compass Therapeutics in a report issued on Wednesday, August 14th. Wedbush analyst R. Driscoll now anticipates that the company will post earnings of $1.91 per share for tAugust 15, 2024 | marketbeat.comCompass Therapeutics (NASDAQ:CMPX) Announces Quarterly Earnings Results, Meets EstimatesCompass Therapeutics (NASDAQ:CMPX - Get Free Report) posted its quarterly earnings data on Monday. The company reported ($0.10) EPS for the quarter, meeting the consensus estimate of ($0.10). The company had revenue of $0.85 million for the quarter.August 13, 2024 | marketbeat.comBuy Rating Affirmed: Compass Therapeutics’ Promising Pipeline and Prudent Financial OutlookAugust 12, 2024 | markets.businessinsider.comCompass Therapeutics Reports 2024 Second Quarter Financial Results and Provides Corporate UpdateAugust 12, 2024 | finance.yahoo.comWedbush Reiterates "Outperform" Rating for Compass Therapeutics (NASDAQ:CMPX)Wedbush reaffirmed an "outperform" rating and issued a $8.00 price objective on shares of Compass Therapeutics in a research note on Wednesday.August 7, 2024 | marketbeat.comCompass Therapeutics to Participate in the Wedbush PacGrow Healthcare ConferenceAugust 7, 2024 | globenewswire.comShort Interest in Compass Therapeutics, Inc. (NASDAQ:CMPX) Expands By 15.2%Compass Therapeutics, Inc. (NASDAQ:CMPX - Get Free Report) was the recipient of a large growth in short interest in the month of June. As of June 30th, there was short interest totalling 1,820,000 shares, a growth of 15.2% from the June 15th total of 1,580,000 shares. Approximately 2.1% of the shares of the stock are sold short. Based on an average daily volume of 354,600 shares, the short-interest ratio is currently 5.1 days.July 17, 2024 | marketbeat.comCompass Therapeutics (NASDAQ:CMPX) Shares Up 0.7%Compass Therapeutics (NASDAQ:CMPX) Trading 0.7% HigherJuly 10, 2024 | marketbeat.comBraidwell LP Has $496,000 Holdings in Compass Therapeutics, Inc. (NASDAQ:CMPX)Braidwell LP cut its stake in Compass Therapeutics, Inc. (NASDAQ:CMPX - Free Report) by 94.7% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 317,761 shares of the company's stock after sellingJune 12, 2024 | marketbeat.comHC Wainwright Reiterates Buy Rating for Compass Therapeutics (NASDAQ:CMPX)HC Wainwright restated a "buy" rating and issued a $10.00 price objective on shares of Compass Therapeutics in a report on Monday.June 3, 2024 | marketbeat.comCompass Therapeutics to Participate in the Jefferies Global Healthcare ConferenceMay 30, 2024 | globenewswire.comMonashee Investment Management LLC Has $780,000 Stock Holdings in Compass Therapeutics, Inc. (NASDAQ:CMPX)Monashee Investment Management LLC decreased its position in shares of Compass Therapeutics, Inc. (NASDAQ:CMPX - Free Report) by 59.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 500,000 shares of the comMay 29, 2024 | marketbeat.comCompass Therapeutics Announces CEO TransitionMay 28, 2024 | globenewswire.comCompass Therapeutics to Present Phase 1 Data for CTX-471, A Novel CD137 Agonist Antibody, Demonstrating Anti-Tumor Activity in Patients Who Have Progressed on Approved PD-1 or PD-L1 Inhibitors at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024May 23, 2024 | globenewswire.com Get Compass Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CMPX and its competitors with MarketBeat's FREE daily newsletter. Email Address ⭕ [URGENT] Buy Alert just triggered (Ad)My absolute favorite stock just hit a critical "buy now" trigger price. Click here for the ticker >>> CMPX Media Mentions By Week CMPX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CMPX News Sentiment▼0.340.59▲Average Medical News Sentiment CMPX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CMPX Articles This Week▼71▲CMPX Articles Average Week Get Compass Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CMPX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies PRTA News PLRX News CRON News RLAY News TYRA News TECX News ERAS News KURA News KROS News DNTH News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CMPX) was last updated on 12/25/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Behind the Markets | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Compass Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Compass Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
